Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Inclusion Criteria:

Signed written informed consent

The signed informed consent
The benefits/risks of the induction chemotherapy regimen will be reviewed, and a second consent may be necessary if the regimen will be administered according to a separate protocol
AML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS (10-19% blasts in marrow by morphology or flow cytometry or blood)
Treatment-related mortality (TRM) score < 9.21 corresponding to a TRM rate of 3% when chemotherapy of similar intensity as proposed here is administered to inpatients
Blast count =< 10,000
Fibrinogen > 200
Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal infection unless determined to be, at the discretion of the investigator, not clinically significant in the context of this study
Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
Patient must have an outpatient caregiver available
Patient must live within 30 minutes of the treating physician's office during outpatient treatment
Patient must be willing to return to the treating physician's office for outpatient follow-up once outpatient treatment is completed

Logistical requirements:

Space available in infusion room
Outpatient infusion pump available if continuous infusion required
Case discussed with infusion room nursing staff